Gossamer Bio is a clinical-stage biopharmaceutical company dedicated to developing and commercializing seralutinib, an inhaled medication aimed at treating pulmonary arterial hypertension (PAH). Seralutinib functions as an inhibitor of PDGFR, CSF1R, and c-KIT, targeting the underlying mechanisms associated with PAH, including proliferation, fibrosis, and inflammation. The company is currently conducting the Phase 3 PROSERA study, which aims to evaluate the efficacy and safety of seralutinib in improving pulmonary hemodynamics and exercise capacity in patients classified as Functional Class II and III according to the World Health Organization.

The clinical development of seralutinib has shown promising results in various studies, including the Phase 2 TORREY study, which assessed its efficacy and safety in PAH patients. Data from these studies indicate that seralutinib exhibits potent efficacy, improving pulmonary arterial blood vessel volume distribution and positively affecting circulating biomarkers related to proliferation, inflammation, and fibrosis. Gossamer Bio's commitment to enhancing the lives of individuals with pulmonary hypertension is reflected in its ongoing research and clinical trials aimed at establishing seralutinib as a viable treatment option for this challenging condition.

United States

We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Our goal is to be an industry leader in each of these therapeutic areas and enhance and extend the lives of patients suffering from such diseases.

Cardiovascular Diseases

Lung Diseases

Gossamer Bio

Lung disease

Pulmonary arterial hypertension

Rare diseases

A novel inhaled PDGFRα/β inhibitor, on PDGFR pathway inhibition and BMPR2 modulation

Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor)

Pulmonary hypertension associated with interstitial lung disease

Seralutinib (GB002)

Cancer

Esophageal cancer

Gastric cancer

Solid tumor/s

GB1275 is a first-in-class, CD11b modulator that reduced MDSCs and TAMs at the tumor site, repolarized M2 immunosuppressive TAMs towards an M1 phenotype, and thus increased tumor infiltration of activated CD8+ T cells in preclinical models in vivo.

GB1275 (Oral CD11b modulator)

Ulcerative colitis

GB004 is an oral, gut-targeted, small molecule that stabilizes hypoxia inducible factor (HIF-1a), a key transcription factor involved in the adaptive and protective cellular responses at the intersection of hypoxia and inflammation

GB004 (Oral HIF-1α stabilizer)

Asthma

GB001 is a potent and highly selective oral prostaglandin D2 receptor 2 (DP2) antagonist in development for moderate-severe asthma &nbsp;and chronic rhinosinusitis&nbsp;

Gossamer Bio

Company Details